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Therapeutic Effect of Montelukast,
a Cysteinyl Leukotriene Receptor 1
Antagonist, on Japanese Patients with
Seasonal Allergic Rhinitis
Kimihiro Okubo1 and Kohtaro Baba2
ABSTRACT
Background: Secretion of nasal discharge was enhanced and airway-resistance in the nasal cavity was aug-
mented, resulting in nasal congestion, when leukotrienes were administered to the nasal mucosa. These re-
sults indicate that leukotrienes play an important role in the pathogenesis of allergic rhinitis.
Methods: A double-blind clinical study was carried out to evaluate the efficacy and the safety of montelukast,
a cysteinyl leukotriene receptor 1 antagonist, 5 mg, 10 mg or placebo orally administered once daily at bedtime
for 2 weeks, to Japanese patients with seasonal allergic rhinitis. The composite nasal symptom scores (aver-
age over the 2-week treatment period) were compared among the montelukast 5 mg and 10 mg groups with
the placebo group.
Results: The composite nasal symptom score significantly improved in the montelukast 5 mg and 10 mg
groups compared with the placebo group. The administration of montelukast 5 mg or 10 mg once daily was well
tolerated and the safety profiles were similar to those of the placebo. There were no significant differences in
the incidences of adverse experience or drug-related adverse experience among the montelukast 5 mg, 10 mg
groups and the placebo group.
Conclusions: Both montelukast 5 mg and 10 mg doses show clinically meaningful efficacy for the treatment
of patients with seasonal allergic rhinitis and the safety profiles of those are comparable to that of the placebo.
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INTRODUCTION
Allergic rhinitis is a type-I allergic disorder of nasal
mucosa as characterized by nasal symptoms such as
sneezing, nasal discharge and nasal congestion, while
allergic reactions are triggered in the nasal mucosa
when aspirating antigens in the air (house-dust, mite,
and cedar pollen, etc.) through the nose.1 The inci-
dence of allergic rhinitis has been estimated to be ap-
proximately 10%―20%2 (pollinosis: 10％―15%) and the
incidences have been rising in Japan. Symptomati-
cally, allergic rhinitis is broadly classified into two
phases, i.e., immediate phase and delayed phase.
During the immediate phase, allergic rhinitis is char-
acterized by three symptoms such as sneezing, nasal
discharge and nasal congestion, while nasal conges-
tion is the major complaint in the delayed phase.
Cysteinyl leukotrienes (CysLT) and related sub-
stances are lipid-mediators secreted from inflamma-
tory cells. Granulocytes, primarily consisting of
eosinophils, are elevated in nasal discharge secreted
from patients with allergic rhinitis as accompanied by
increases in leukotrienes (LTs).3 In addition, it has
been reported that secretion of nasal discharge was
enhanced and airway-resistance in the nasal cavity
was augmented, resulting in nasal congestion, when
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Table 1 Patient demographics and other baseline characteristics
Montelukast 10 mgMontelukast 5 mgPlaceboTreatment-groups
310318314Number of subjects (Eficacy assessment)
Gender
114 (36.8)109 (34.3) 112 (35.7)†Male
196 (63.2)209 (65.7)202 (64.3)Female
Age (Years)‡
36.4±9.8 37.2±9.7 36.3±9.5 Mean±SD
Body weight (kg)‡
59.6±11.959.0±11.059.7±11.6Mean±SD
Disease type
242 (78.1)249 (78.3)251 (79.9) Seasonal
 68 (21.9) 69 (21.7)63 (20.1)Seasonal＋Perennial
Duration of ilness (Years)‡
14.1±7.8 14.8±8.7 13.6±7.1 Mean±SD
Specific IgE-antibodies
126 (40.6)129 (40.6)139 (44.3) Only cedar＞＿ 2
184 (59.4)189 (59.4)175 (55.7) ＞＿ 2 types: ＞＿ 2 antibodies
Skin test
 65 (21.0) 59 (18.6)56 (17.8)Negative
236 (76.1)248 (78.0)248 (79.0) Positive
 9 (2.9)11 (3.5)10 (3.2) Indeterminable
Baseline symptomatic scores (Mean±SD)
1.52±0.431.54±0.461.53±0.45Composite nasal symptom scores
1.83±0.451.87±0.501.86±0.48Daytime nasal symptom scores
1.20±0.541.20±0.541.19±0.55Nightime nasal symptom scores
†Number of patients (%).
‡ANOVA was used to test homogeneity of age, body weight and duration of ilness, while the chi-square test was used for other patient 
characteristics.
LTs were administered to the nasal mucosa experi-
mentally.4 These results indicate that LTs play a clini-
cally meaningful role in the pathogenesis of allergic
rhinitis.
Montelukast is a cysteinyl leukotriene receptor 1
(CysLT1) antagonist that has been developed primar-
ily intended for the treatment of bronchial asthma.1
Montelukast has been marketed for adult and pediat-
ric patients with bronchial asthma since 1997, and is
currently marketed in a number of countries. Since
montelukast has been expected to be effective not
only for the treatment of bronchial asthma but also
for improvement of symptoms associated with aller-
gic rhinitis based on its mechanisms of actions, its
clinical development was initiated as a medication for
allergic rhinitis. The clinical studies of montelukast
have been performed overseas in patients with sea-
sonal and perennial allergic rhinitis and its usefulness
was demonstrated.5
In Japan, we conducted a double blind clinical
study in patients with seasonal allergic rhinitis using
montelukast 5-mg and 10-mg tablets as well as the
placebo tablets in order to develop a new medication
for allergic rhinitis as characterized by “easy to use”,
“highly effective” and “very safe”. In conclusion, we
have demonstrated the efficacy and the safety of mon-
telukast in Japanese patients with seasonal allergic
rhinitis in the present study.
METHODS
PATIENTS
The demographics and the other baseline character-
istics of 945 patients (942 patients for efficacy analy-
sis) treated with montelukast 5 mg, 10 mg or placebo,
are described in Table 1. Patients were treated as out
patients at 24 institutions. The patients were seasonal
allergic rhinitis patients who fulfilled the inclusion cri-
teria listed as follows: (1) quantitative analysis of spe-
cific IgE antibody (UniCAP-RAST) revealed scores =
2 points (containing antibodies against pollen scat-
tered between February and April, 2003); (2) a past
history of typical seasonal allergic rhinitis at least for
the past two years; (3) age: between 15 and 65 years
(male or female), (4) the following two criteria ful-
filled for symptoms6,7 [(1) total scores of daytime na-
sal symptoms (sneezing attacks, nasal discharge and
nasal congestion during the day) = 4 points per day,
as an average (total = 12 points) and (2) total scores
of nighttime nasal symptoms (difficulties in falling
into sleep, nasal congestion at night, and degree of
Montelukast on Allergic Rhinitis (1)
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Table 2 Severity of daytime nasal symptoms (DNSS)
Severity
Types
－＋＋＋＋＋＋＋＋＋＋
None1―5 times6―10 times11―20 times＝21 timesSneezing
None1―5 times6―10 times11―20 times＝ 21 timesNasal discharge 
(frequencies)
NoneNo oral-breathing, 
but nasal congestion 
(＋)
Severe nasal con-
gestion with occa-
sional oral-breathing
Very severe nasal-
congestion with fre-
quent oral-breathing
Complete conges-
tion, al day
Nasal congestion
If scored, ＋＋＋＋: 4-points, ＋＋＋: 3-points, ＋＋: 2-points, ＋: 1-point, －: 0-point.
Daytime symptoms: after rising until bedtime.
Adopted from the Practical Guideline for the Management of Alergic Rhinitis in Japan, 2002 edition (the Fourth Revised Edition)7.
Table 3 Severity of nightime nasal symptoms (NNSS)
Severity
Types
－＋＋＋＋＋＋＋＋＋＋
Not at alSlightly badBadVery badUnable to sleep 
at al
Dificulty in faling 
asleep
No nasal
congestion
Nasal conges-
tion (＋), but not 
bothering
Nasal congestion occa-
sionaly bothered
Persistent nasal 
congestion with 
oral-breathing
Severe nasal con-
gestion with persis-
tent oral-breathing
Nasal congestion 
at night
NoneOnce2 times3 times＝ 4 timesAwakening at night
If scored, ＋＋＋＋: 4-points, ＋＋＋: 3-points, ＋＋: 2-points, ＋: 1-point, －: 0-point.
Nightime symptoms: after bedtime until rising the folowing morning.
awakening at night) = 2 points per day, as an average
(total = 6 points)] (Tables 2, 3). The study was per-
formed when the patients fulfilled these two inclusion
criteria. The patients with nasal disorders that might
interfere with the efficacy assessment, or those using
drugs that might interfere with the efficacy assess-
ment were excluded from the study. Patients who
used any drug that might affect efficacy assessment
in the study within 2 weeks before the run-in period
such as anti-histamines, leukotriene receptor antago-
nists, anti-thromboxane A2 drugs, chemical mediator
release inhibitors, Th2 cytokine inhibitors, corti-
costeroids (topical and systemic), vasoconstrictors,
parasympathetic nerve blockers (anti-cholinergic),
biological preparations (histamine-containing immu-
noglobulin), tranquilizers (anti-depressants, anti-
psychotics, and CNS suppressants), and the other
drugs with similar pharmacological activities to the
above-mentioned drugs (herbal medications that are
expected to have anti-allergic action, but common
cold medication can be used when necessary). Bron-
chial asthma patients with uncontrolled mild to mod-
erate symptoms and patients with severe bronchial
asthma were excluded from the study.
STUDY DESIGN
The study was a double blind, randomized, placebo-
controlled, multi-center dose-finding study, con-
ducted during the spring season in 2004. The study
period consisted of a four-day run-in period and two-
week treatment period. The treatment period was de-
termined by the previous overseas results that mon-
telukast reached its almost maximal therapeutic ef-
fect, compared with placebo within 2 weeks.5 The pa-
tients were randomized in a 1 : 1 : 1 ratio to receive
either montelukast 5 mg, 10 mg, or placebo groups.
Montelukast sodium 5-mg and 10-mg tablets and the
matching placebo tablets (Banyu Pharmaceutical Co.,
Ltd.) were orally administered once daily at bedtime
for two weeks. The study protocol was approved by
each institutional review board, and all patients gave
written informed consent to participate. The patients,
who fulfilled the inclusion criteria without violating
any of the exclusion criteria, were enrolled after the
informed consent to participate in this study was ob-
tained. Nasal symptoms based on physical examina-
tions and rhinitis-diaries were checked at every pa-
tient visit. Clinical and laboratory examinations were
performed to assess the safety at the time of initiation
of the therapy and at week-2 of treatment or at the
time of discontinuation.
EVALUATION OF EFFICACY AND SAFETY
As a primary endpoint, daily mean of the composite
nasal symptom scores (CNSS) (average of nasal
symptom scores during the daytime and the night-
Okubo K et al.
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Fig. 1 Mean change from baseline in the composite nasal 
symptom scores for the 2-week treatment period. ＊ p ＜
0.01.
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time) over a 2 week treatment period, were compared
with those during the period. As secondary end-
points, the following symptoms were investigated: (1)
daytime nasal symptoms scores (DNSS) (mean score
of nasal congestion, nasal discharge and sneezing),
(2) nighttime nasal symptoms scores (NNSS) (mean
score of severity of nasal congestion at night, diffi-
culty in falling asleep and degree of awakening at
night), (3) Composite nasal congestion scores (mean
of nasal congestion scores during the day and at
night). In addition, patient and investigator impres-
sions were assessed with regards to the efficacy. The
use of CNSS, DNSS and NNSS as the primary and
secondary endpoints has been recommended in the
Guidance for Industry, Allergic Rhinitis: Clinical De-
velopment for Programs for Drug Products (FDA
CDER, www.fda.govcderguidance2718dft.htm,
last updated on March 08, 2001).
Clinical and laboratory adverse experiences were
investigated. The drug-related adverse experiences
were also evaluated.
STATISTICAL ANALYSIS
The full analysis set (FAS) was defined as the pri-
mary efficacy analysis population. Comparison of the
change from the baseline over 2 weeks in the CNSS
between the treatment groups were performed using
an analysis of covariance (ANCOVA) model which
contains the treatment group and the study site as
factors and the baseline as a covariate. A step-down
procedure was used in the between-group compari-
son. The onset of action was evaluated via compari-
sons of montelukast with the placebo using the same
ANCOVA model at Day 3, Day 2 and Day 1 in a step-
down procedure. The patient and investigator impres-
sions were analyzed (the percentage of “much im-
proved” and “improved”) using a logistic regression
model via a step-down procedure.
The incidences of adverse experiences (AE) and
drug-related AE as well as their 95% confidence inter-
vals were calculated, and those were compared using
Fisher’s exact test.
RESULTS
A total of 945 patients was randomized (316, 319 and
310 patients for placebo, montelukast 5 mg and 10
mg groups, respectively), and 917 patients completed
the study, while 28 patients (9, 12 and 7 patients for
placebo, montelukast 5 mg and 10 mg groups, re-
spectively) discontinued the study. Among them, 943
patients were eligible for safety analysis, excluding
two patients (one for the placebo group due to the in-
formed consent withdrawal and another for the mon-
telukast 5 mg group due to not visiting the study
site). In addition, 942 patients were eligible for effi-
cacy analysis, excluding one patient (the placebo
group). The patient characteristics for efficacy analy-
sis are summarized in Table 1. There were no clini-
cally significant differences of the baseline patient
characteristics among the three treatment groups.
EFFICACY ANALYSIS
The changes from the baseline (LS mean ± SE) in the
CNSS over 2 weeks for each treatment group are
shown in Figure 1. The LS mean changes from the
baseline in the CNSS over 2 weeks were −0.37, −0.47
and −0.47 points for the placebo, montelukast 5 mg
and 10 mg groups, respectively, demonstrating sig-
nificant improvements in montelukast (5 mg and 10
mg) compared with the placebo (P = 0.001 for both
groups). There was no significant difference between
montelukast 5 mg and 10 mg groups.
The change from the baseline (LS mean ± SE) in
the DNSS over 2 weeks for each treatment group is
shown in Figure 2. The LS mean changes from the
baseline in the DNSS over 2 weeks were −0.33, −0.43
and −0.44 points for the placebo, montelukast 5 mg
and 10 mg groups, respectively, demonstrating sig-
nificant improvements in montelukast (5 mg and 10
mg) compared with the placebo (P = 0.002 and P =
0.004, respectively).
As for each component of the nasal symptom
scores, the change from the baseline (LS mean) in
the daytime nasal congestion scores over 2 weeks
were −0.31, −0.42 and −0.44 points for the placebo,
montelukast 5 mg and 10 mg groups, respectively,
demonstrating significant improvements in montelu-
kast (5 mg and 10 mg) compared with the placebo (P
= 0.004 and P = 0.011, respectively).
The changes from the baseline (LS mean) in the
mean nasal discharge scores for the 2-week treat-
ment period were −0.33, −0.46 and −0.44 points for
the placebo, montelukast 5 mg and 10 mg groups, re-
Montelukast on Allergic Rhinitis (1)
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Fig. 2 Mean change from baseline in symptom scores of the daytime nasal symptoms during 2-week treatment period. 
＊ p ＜0.01.
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spectively, demonstrating significant improvements
in montelukast (5 mg and 10 mg) compared with the
placebo (P = 0.010 and P = 0.003, respectively).
The changes from the baseline (LS mean) in the
mean sneezing scores for the 2-week treatment pe-
riod were −0.34, −0.41 and −0.44 points for the pla-
cebo, montelukast 5 mg and 10 mg groups, respec-
tively, demonstrating significant improvements in
montelukast 10 mg compared with the placebo (P =
0.013). There was no significant difference between
the placebo and montelukast 5 mg groups (P =
0.073).
Thus, there were no significant differences in any
of the efficacy parameters above between montelu-
kast 5 mg and 10 mg groups.
The change from the baseline (LS mean) in the
NNSS over 2 weeks for each treatment group is
shown in Figure 3. The changes from the baseline
(LS mean) in the NNSS over 2 weeks were −0.40,
−0.50 and −0.51 for the placebo, montelukast 5 mg
and 10 mg groups, respectively, demonstrating sig-
nificant improvements in montelukast (5 mg and 10
mg) compared with the placebo (P = 0.002 and P =
0.003, respectively).
The changes from the baseline (LS mean) in the
nighttime nasal congestion scores over 2 weeks were
−0.49, −0.63 and −0.62 points for the placebo, mon-
telukast 5 mg and 10 mg groups, respectively, dem-
onstrating significant improvements in montelukast
(5 mg and 10 mg) compared with the placebo (P =
0.007 and P = 0.003, respectively).
The changes from the baseline (LS mean) in the
mean scores of difficulties in falling into sleep at night
for the 2-week treatment period were −0.43, −0.51 and
−0.54 points for the placebo, montelukast 5 mg and 10
mg groups, respectively, demonstrating significant
improvements in montelukast (5 mg and 10 mg) com-
pared with the placebo (P = 0.004 and P = 0.027, re-
spectively).
The changes from the baseline (LS mean) in the
mean scores of extent of awakening at night for the 2-
week treatment period were −0.30, −0.37 and −0.38
points for the placebo, montelukast 5 mg and 10 mg
groups respectively, demonstrating significant im-
provements in montelukast (5 mg and 10 mg) com-
pared with the placebo (P = 0.013 and P = 0.016, re-
spectively).
The changes from the baseline (LS mean) in the
mean scores of Composite nasal congestion score for
the 2-week treatment period were −0.52, −0.53 and
−0.40 points for the placebo, montelukast 5 mg and 10
mg groups respectively, demonstrating significant im-
provements in montelukast (5 mg and 10 mg) com-
pared with the placebo (P = 0.003 and P = 0.002, re-
spectively).
Thus, there were no significant differences in any
of the efficacy parameters above between montelu-
kast 5 mg and 10 mg groups.
There was significant difference in the impression
rates of patient impressions only between montelu-
kast 10 mg group and the placebo group (montelu-
kast 10 mg group: P = 0.036, montelukast 5 mg
Okubo K et al.
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Fig. 3 Mean change from baseline in symptom scores of the nightime nasal symptoms during the 2-week-treatment period. 
＊ p ＜0.01.
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group: P = 0.144).
There was no significant difference in the impres-
sion rates of investigator impressions between the
montelukast 10 mg group and the placebo group (P =
0.250). Thus, the impression rates of investigator im-
pressions between the montelukast 5 mg group and
the placebo group were not compared.
ANALYSIS OF THE ONSET OF ACTION
To assess the time of onset of action of montelukast,
the changes from the baseline in the CNSS, DNSS
and NNSS at Day 1, 2 and 3 in the montelukast
groups were compared with those of the placebo
group (Fig. 4). There were significant between-group
differences in the CNSS and DNSS in the montelu-
kast 10 mg group compared with the placebo group
from Day 1 (P < 0.05). Similarly, there were signifi-
cant differences in the NNSS between the montelu-
kast 10 mg group and the placebo group from Day 2
(P < 0.01). In addition, there were significant differ-
ences in the CNSS between the montelukast 5 mg
group and the placebo group from Day 2 (P < 0.05),
while there were significant differences in the DNSS
between the montelukast 5 mg group and the placebo
group from Day 3. However, there was no significant
difference in the NNSS between the montelukast 5
mg group and the placebo group.
SAFETY ANALYSIS
There were no clinically meaningful differences be-
tween the treatment groups in the incidence of clini-
cal and laboratory adverse experiences (AE). The in-
cidences of AE were 26.3%, 29.9% and 26.5% for clini-
cal AE and 6.0%, 7.2% and 9.0% for laboratory AE in
the placebo, montelukast 5 mg and 10 mg groups, re-
spectively. There was also no significant difference in
the incidence of drug-related clinical or laboratory AE
among the three groups. The incidences of drug-
related AE were 4.1%, 4.7% and 4.2% for clinical AE
and 3.2%, 1.9% and 5.8% for laboratory AE in the pla-
cebo, montelukast 5 mg and 10 mg groups, respec-
tively. There were no serious AE and no fatalities.
“Headache”, “constipation”, “thirst” and “somno-
lence” were common drug-related AE occurring in
more than 2 cases (approximately 1%) in any of the
three groups. All drug-related clinical AE were mild
or moderate. In addition, one patient terminated the
study due to the drug-related AE, severe “pruritus”
and “nausea”, in the montelukast 5 mg group. The pa-
tient recovered thereafter.
“Blood bilirubin increased”, “blood triglycerides in-
creased”, “urinary occult blood positive” and “protein
urine present” were drug-related laboratory AE oc-
curring in more than 2 cases (approximately 1%) as-
signed to at least one of the three groups. All drug-
related laboratory AE were transient in the
montelukast-treated groups, and all of them recov-
ered or improved without any treatment.
Montelukast on Allergic Rhinitis (1)
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Fig. 4 Mean change from baseline in the composite, the daytime and the nightime nasal symptom scores through Day 1 to 
Day 3 (LS mean and its 95% confidence interval).●: Placebo Group ▲: Montelukast 5-mg group ■: Montelukast 10-mg group. 
＊P＜0.05, ＊＊P＜0.01 (Comparison versus placebo group).
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DISCUSSION
Steroid preparations and leukotriene antagonists
have been used for the treatment of allergic rhinitis,
in particular, as medications for nasal congestion.7 In
this study, montelukast once daily treatment has
been indeed demonstrated to be efficacious for treat-
ment of nasal congestion. Montelukast alleviated not
only nasal congestion but also general symptoms as-
sociated with allergic rhinitis, including sneezing and
nasal discharge. This may be attributable to its anti-
inflammatory activity besides antagonistic actions
against leukotriene receptors located in surrounding
blood vessels.
Montelukast can be expected to be used as a treat-
ment for nasal congestion by its mechanism of airflow
resistance improvement in the nasal cavity, which has
been demonstrated in non-clinical and clinical stud-
ies.8,9 Anti-histamines, anti-allergic agents, corti-
costeroids (nasal drops) and vasoconstrictors are
used for the treatment of allergic rhinitis at present.
Therapeutic agents except for corticosteroid partially
showed therapeutic effects on sneezing and nasal dis-
charge, but not on nasal congestion. In addition, it is
difficult for elderly patients to take inhaled corti-
costeroids in the delivery technique. Thus, simple
Okubo K et al.
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oral administration of montelukast, a cysteinyl leukot-
riene receptor antagonist, is considered to have an
advantage in therapeutic effect on nasal congestion in
addition to sneezing and nasal discharge. Both the
montelukast 5 mg 10 mg groups showed significant
improvement compared with placebo for many secon-
dary endpoints including the Composite nasal symp-
toms score in the present study.
The primary endpoint of the CNSS was improved
significantly in both montelukast 5 mg and 10 mg
groups compared with the placebo group. The
between-group difference in the changes from the
baseline (LS mean) between montelukast (5 mg and
10 mg) and the placebo was −0.11 points, suggesting
that the efficacy of montelukast in Japanese patients
was comparable with the results of clinical studies
conducted overseas in non-Japanese patients with
seasonal allergic rhinitis.5,10-14 Several efficacy pa-
rameters, including the DNSS and the NNSS, also im-
proved to some extent in both the montelukast 5 mg
and 10 mg groups, compared with the placebo group,
which were similar to the CNSS.
In this study, we investigated time needed for ex-
erting the efficacy and found that the CNSS improved
to some extent in the montelukast 10 mg group, start-
ing on Day 1. The CNSS improved to some extent,
starting on Day 2 in the montelukast 5 mg group.
Taken together, these results demonstrated that
montelukast exerts fast acting pharmacological ef-
fects which were similar to the results in the previous
study.15 The early onset of action could be beneficial
to allergic rhinitis patients.
Patient impressions (improved or better) and fre-
quency of sneezing (mean scores for the 2-week
treatment period) improved to some extent only in
the montelukast 10 mg group, but not in the montelu-
kast 5 mg group, as compared with the placebo
group.
When the efficacy was analyzed according to the
baseline symptoms severity subgroup, the CNSS im-
proved to some extent only in the montelukast 10 mg
group, as compared with the placebo group, among
patients with severe symptoms (the CNSS ≧1.5
points as an average and the NNSS ≧1.0 point as an
average during the run-in period) (data not shown),
although the montelukast 5 mg and 10 mg groups
showed similar efficacy in the primary endpoint. The
study was conducted in the spring of 2004 when an-
nual pollen-amount was approximately 15 of that
seen in usual years in Japan. Taking the pollen-
amount into consideration, the data suggest that
montelukast may be clinically useful for treating sea-
sonal allergic rhinitis at a dose of 10 mg in patients
with severe symptoms. It has been also reported that
the incidence of complications with allergic rhinitis
was 59.4% in adult patients and 79% in pediatric pa-
tients with bronchial asthma in Japan.16
We investigated the safety, based on the incidence
of clinical and laboratory adverse experiences, and
there were no significant or clinically meaningful dif-
ferences in the incidence of adverse experiences and
drug-related adverse experiences among the three
groups. With regard to laboratory AE, there were no
significant differences in the incidence of adverse ex-
periences and drug-related adverse experiences
among the three groups. No serious adverse experi-
ences occurred in any of the three groups. All drug-
related adverse experiences were transient in the
montelukast-treated groups, and all of them recov-
ered or showed a trend of recovery. These results
demonstrated the clinical usefulness of montelukast
from the standpoint of safety. In addition, there was
no difference in the safety profiles between montelu-
kast (5 mg and 10 mg) and the placebo groups, dem-
onstrating that montelukast was well tolerated and
safe in patients with allergic rhinitis following its ad-
ministration for two weeks. Thus, montelukast once
daily is one of the therapeutic alternatives for allergic
rhinitis, and useful not only for the treatment for na-
sal congestion but also for improving allergic symp-
toms in general.
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